European Journal of Chemistry

Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone

Main Article Content

Kamelia Mahmoud Amin
Ossama Metwally El-Badry
Doaa Ezzat Abdel Rahman
Usama Magdi Ammar
Mohamed Mostafa Abdalla


Design and synthesis of some new pyridopyrazinone derivatives as anti-proliferative agents is described. The cytotoxic activities of the synthesized compounds against melanoma cell line (LOXIMVI), ovarian cell line (OVCAR3), thyroid cell lines (CAL62, FTC133, BCPAP and ML1) and colon cell lines (HT29 and HCT116) were investigated. Results revealed that most compounds were active and compound 3d was the most active one. It exhibited promising activity against all tested cell lines. In addition, in vitro kinase assay against both WTBRAF and V600EBRAF was performed for all synthesized compounds. Furthermore, molecular docking of tested compounds was established with active site of V600EBRAF kinase domain. Results of kinase inhibition assay and molecular docking revealed that, compounds 1, 3d, e, h, i, 5d, e and 6b were potent inhibitors for V600EBRAF kinase enzyme involved in number of cancer types as melanoma, ovarian and thyroid cancer. The newly synthesized pyridopyrazinones substituted with different substituents at C-3 or fused with triazine heterocycle at C-3 and C-4 afforded potent V600EBRAF inhibitors and exhibited promising cytotoxic activities against different cancer types such as melanoma, ovarian, thyroid and colon cancer.

icon graph This Abstract was viewed 2136 times | icon graph Article PDF downloaded 786 times

How to Cite
Amin, K. M.; El-Badry, O. M.; Rahman, D. E. A.; Ammar, U. M.; Abdalla, M. M. Design, Synthesis, Anticancer Evaluation and Molecular Docking of New V600EBRAF Inhibitors Derived from Pyridopyrazinone. Eur. J. Chem. 2016, 7, 19-29.

Article Details

Crossref - Scopus - Google - European PMC

[1]. Gupta, S. Chem. Rev. 1994, 94 (6), 1507-1551.

[2]. Sparano, J. A., In Molecular Targeting in Oncology, Springer: 2008, pp 55-73.

[3]. Sebolt-Leopold, J. S.; Herrera, R. Nat. Rev. Cancer 2004, 4(12), 937-947.

[4]. Zebisch, A.; Troppmair, J. Cell. Mol. Life Sci. CMLS 2006, 63(11), 1314-1330.

[5]. Wan, P. T.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Project, C. G.; Jones, C. M.; Marshall, C. J.; Springer, C. J. Cell 2004, 116(6), 855-867.

[6]. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W. Nature 2002, 417(6892), 949-954.

[7]. Garnett, M. J.; Marais, R. Cancer cell 2004, 6(4), 313-319.

[8]. Dibb, N. J.; Dilworth, S. M.; Mol, C. D. Nat. Rev. Cancer 2004, 4(9), 718-727.

[9]. Cohen, Y.; Xing, M.; Mambo, E.; Guo, Z.; Wu, G.; Trink, B.; Beller, U.; Westra, W. H.; Ladenson, P. W.; Sidransky, D. J. Cancer Inst. Natl. 2003, 95(8), 625-627.

[10]. Xu, X.; Quiros, R. M.; Gattuso, P.; Ain, K. B.; Prinz, R. A. Cancer Res. 2003, 63(15), 4561-4567.

[11]. Lee, J. H.; Lee, E. S.; Kim, Y. S. Cancer 2007, 110(1), 38-46.

[12]. Hong, D. S.; Vence, L.; Falchook, G.; Radvanyi, L. G.; Liu, C.; Goodman, V.; Legos, J. J.; Blackman, S.; Scarmadio, A.; Kurzrock, R. Clin. Cancer Res. 2012, 18(8), 2326-2335.

[13]. Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Nature 2007, 445(7130), 851-857.

[14]. Whittaker, S.; Menard, D.; Kirk, R.; Ogilvie, L.; Hedley, D.; Zambon, A.; Lopes, F.; Preece, N.; Manne, H.; Rana, S. Cancer Res. 2010, 70(20), 8036-8044.

[15]. Hoeflich, K. P.; Gray, D. C.; Eby, M. T.; Tien, J. Y.; Wong, L.; Bower, J.; Gogineni, A.; Zha, J.; Cole, M. J.; Stern, H. M. Cancer Res. 2006, 66(2), 999-1006.

[16]. Karasarides, M.; Chiloeches, A.; Hayward, R.; Niculescu-Duvaz, D.; Scanlon, I.; Friedlos, F.; Ogilvie, L.; Hedley, D.; Martin, J.; Marshall, C. J. Oncogene 2004, 23(37), 6292-6298.

[17]. Eisen, T.; Ahmad, T.; Flaherty, K.; Gore, M.; Kaye, S.; Marais, R.; Gibbens, I.; Hackett, S.; James, M.; Schuchter, L. Br. J. Cancer 2006, 95(5), 581-586.

[18]. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M. Cancer Res. 2004, 64(19), 7099-7109.

[19]. Ratain, M. J.; Eisen, T.; Stadler, W. M.; Flaherty, K. T.; Kaye, S. B.; Rosner, G. L.; Gore, M.; Desai, A. A.; Patnaik, A.; Xiong, H. Q. J. Clin. Oncol. 2006, 24(16), 2505-2512.

[20]. King, A. J.; Patrick, D. R.; Batorsky, R. S.; Ho, M. L.; Do, H. T.; Zhang, S. Y.; Kumar, R.; Rusnak, D. W.; Takle, A. K.; Wilson, D. M. Cancer Res. 2006, 66(23), 11100-11105.

[21]. El-Nassan, H. B. Eur. J. Med. Chem. 2014, 72, 170-205.

[22]. Liao, J. J. L. J. Med. Chem. 2007, 50 (3), 409-424.

[23]. Mosmann, T. J. Immunol. Methods 1983, 65(1), 55-63.

[24]. Hansen, M. B.; Nielsen, S. E.; Berg, K. J. Immunol. Methods 1989, 119(2), 203-210.

[25]. Qin, J.; Xie, P.; Ventocilla, C.; Zhou, G.; Vultur, A.; Chen, Q.; Liu, Q.; Herlyn, M.; Winkler, J.; Marmorstein, R. J. Med. Chem. 2012, 55(11), 5220-5230.

[26]. Kim, J. E.; Leung, E.; Baguley, B. C.; Finlay, G. J. Front. Genet. 2013, 4(97), 1-8.

[27]. Molecular Operating Environment (MOE), Chemical Computing Group, Canada, Operating_Environment.htm.

[28]. Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K. Proc. Natl. Acad. Sci. 2008, 105(8), 3041-3046.

[29]. Leese, C.; Rydon, H. J. Chem. Soc. 1955, 303-309.

[30]. Bahadur, S.; Pandey, K. Indian Chem. Soc. 1980, 57(4), 447-448.

[31]. Westphal, G.; Wasicki, H.; Zielinski, U.; Weber, F.; Tonew, M.; Tonew, E. Pharmazie 1977, 32(10), 570.

[32]. Tarzia, G.; Occelli, E.; Toja, E.; Barone, D.; Corsico, N.; Gallico, L.; Luzzani, F. J. Med. Chem. 1988, 31(6), 1115-1123.

[33]. Roskoski, R. Biochem. Biophys. Res. Commun. 2010, 399(3), 313-317.

[34]. Wang, X.; Kim, J. J. Med. Chem. 2012, 55(17), 7332-7341.

Supporting Agencies

Most read articles by the same author(s)

Dimensions - Altmetric - scite_ - PlumX

Downloads and views


Download data is not yet available.


Metrics Loading ...
License Terms

License Terms


Copyright © 2024 by Authors. This work is published and licensed by Atlanta Publishing House LLC, Atlanta, GA, USA. The full terms of this license are available at and incorporate the Creative Commons Attribution-Non Commercial (CC BY NC) (International, v4.0) License ( By accessing the work, you hereby accept the Terms. This is an open access article distributed under the terms and conditions of the CC BY NC License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited without any further permission from Atlanta Publishing House LLC (European Journal of Chemistry). No use, distribution, or reproduction is permitted which does not comply with these terms. Permissions for commercial use of this work beyond the scope of the License ( are administered by Atlanta Publishing House LLC (European Journal of Chemistry).